Jasper Therapeutics Inc JSPR
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-11-20 |
| Shares Out. | 33,270,000 |
| Website | jaspertx.com/ ↗ |
| Phone | 16505491400 |
| Employees | 22 |
| Net Income | -$1.2M |
| Free Cash Flow | -$68.9M |
| Total Assets | $21.2M |
| Total Liabilities | $17.8M |
| Equity | $3.4M |
About Jasper Therapeutics Inc
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
Jasper Therapeutics Inc is a publicly traded company under the ticker symbol JSPR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-07-01)